HOME >> BIOLOGY >> NEWS
Stanford's new antigen microarrays open window to better disease screening

STANFORD, Calif. - Your immune system normally protects against disease, but in some cases - such as with rheumatoid arthritis, lupus, and type-I diabetes - the immune system actually attacks your body. Until now, these disorders, called autoimmune diseases, have been difficult to diagnose and treat. But a new microarray-based technology developed at Stanford University Medical Center may help solve the problem.

Antigen microarrays, as reported in the March issue of Nature Medicine, give doctors a glimpse of which molecules (antigens) come under attack in an autoimmune disease. By identifying these antigens, doctors can pinpoint diseases and treatment options.

"Right now clinicians test each antigen separately - and each one can take weeks," said P.J. Utz, MD, assistant professor of immunology and rheumatology and senior author on the study. "These arrays could enable a clinician to diagnose the disease on the first visit."

The antigen microarrays - developed in collaboration with Lawrence Steinman, MD, professor of neurology and neurological sciences - consist of glass slides dotted with thousands of proteins and other molecules that are often attacked in autoimmune diseases. To use the microarray, doctors draw a blood sample from the patient and incubate it on the array. Those antibodies that attack molecules on the array will locate their target and latch on. Fluorescent molecules are then added to detect the antibodies, creating colored spots on the slide. From there, it's a matter of counting the spots to see which antigens the immune system recognized.

In normal people, the antibodies will ignore most antigens on the array. Diabetics, however, may produce arrays with spots corresponding to pancreas cell proteins, and people with rheumatoid arthritis produce spots that correspond to molecules found in the joints.

Utz and William Robinson, MD, PhD, a fellow in the division of immunolo
'"/>

Contact: Amy Adams
amyadams@stanford.edu
650-723-3900
Stanford University Medical Center
6-Mar-2002


Page: 1 2

Related biology news :

1. Researchers go fishing, pull out antigens
2. Hopkins researchers identify transplantation antigens among Sioux Indians
3. Cyclin B1 identified as a new tumor antigen and candidate for the development of a cancer vaccine
4. UC Berkeley group finds first prostate cancer antigen, providing hope for an eventual vaccine against the tumor
5. UroGenesys researchers discover new target antigen for prostate cancers
6. Library on a Slide: Whole genome microarrays for comparative genomics
7. Study by Tufts biologist provides window into progression of some degenerative diseases
8. Film found on windows after 9/11 reveals higher level of pollutants
9. Germ-free transparent fish open new window into gut development
10. Yeast mutations offer window into human disease
11. New findings are a window into the late stages of Lou Gehrigs disease

Post Your Comments:
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
(Date:8/26/2015)... ... August 26, 2015 , ... Lee ... in the development and manufacture of highly valued cardiac markers used in early ... extensive expertise with protein chemistry has led to the development and commercialization of ...
(Date:8/26/2015)... GERMANTOWN, Md. , Aug. 26, 2015 ... synthetic biology, announced today the closing of its previously ... in full by the underwriters of their option to ... the public offering price of $41.00 per share.  The ... of shares of common stock sold by Intrexon to ...
(Date:8/26/2015)... , August 26, 2015 After litigating ... Europlasma NV relating to P2i United States ... their dispute in the United States ... the part of either party. As a result of the ... of California dismissed the case without ...
(Date:8/26/2015)... ... 2015 , ... The 2015 Epigenomics & Metabolomics Meeting in Boston ... Asymmetrex to share the first report on progress with its crowdsourcing campaign designed ... tissue stem cells. , With a name like “H2A.Z asymmetry,” the new biomarker would ...
Breaking Biology Technology:Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
Cached News: